Dataset from A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer

This randomized, open-label study will evaluate the efficacy and safety of atezolizumab
compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per
investigator discretion) combined with either pemetrexed (non-squamous disease) or
gemcitabine (squamous disease) in programmed death-ligand 1 (PD-L1)-selected,
chemotherapy-naive participants with Stage IV Non-Squamous or Squamous NSCLC.